1-5 of 5
Xiaolin Fan, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes

Giuseppe Saglio, Andreas Hochhaus, MD, Timothy P. Hughes, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Hirohisa Nakamae, MD, PhD, Dong-Wook Kim, MD, PhD, Saengsuree Jootar, Gabriel Etienne, MD, PHD, Ian Flinn, MD, PhD, Jeffrey H. Lipton, MD, PhD, Ricardo Pasquini, MD, PhD, Beatriz Moiraghi, MD, Charisse Kemp, Xiaolin Fan, PhD, Hans D. Menssen, MD, PhD, Hagop M. Kantarjian, MD, Richard A. Larson, MD
Journal: Blood
Blood (2013) 122 (21): 92.
https://doi.org/10.1182/blood.V122.21.92.92
Published: 2013
Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients)

Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, Giuseppe Saglio, François Guilhot, Haifa Kathrin Al-Ali, MD, Giantonio Rosti, Chiaki Nakaseko, MD, PhD, Carmino Antonio De Souza, PhD, Charisse Kemp, Xiaolin Fan, PhD, Albert Hoenekopp, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2012) 120 (21): 167.
https://doi.org/10.1182/blood.V120.21.167.167
Published: 2012
Journal Articles

Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Hagop M. Kantarjian, MD, Dong-Wook Kim, MD, Surapol Issaragrisil, MD, Richard E Clark, Josy Reiffers, MD, Franck E. Nicolini, MD, PhD, Ricardo Pasquini, Matt Kalaycio, MD, Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD, Charisse Kemp, Xiaolin Fan, PhD, Roger J. Waltzman, MD, Giuseppe Saglio, MD, Richard A. Larson, MD
Journal: Blood
Blood (2012) 120 (21): 1676.
https://doi.org/10.1182/blood.V120.21.1676.1676
Published: 2012
Journal Articles

Assessment of Patient Reported Outcomes (PROs) From the Enestnd Trial with Minimum Follow-up of 36 Cycles.

Jennifer L Beaumont, MS, Matthew Magestro, John Coombs, PharmD, MBA, Xiaolin Fan, PhD, Charisse Kemp, Roger J. Waltzman, MD
Journal: Blood
Blood (2012) 120 (21): 3166.
https://doi.org/10.1182/blood.V120.21.3166.3166
Published: 2012
Journal Articles

Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,

Philipp D. le Coutre, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Javier Pinilla-Ibarz, MD, PhD, Richard A. Larson, MD, Norbert Gattermann, MD, Oliver G. Ottmann, MD, PhD, Andreas Hochhaus, MD, Jerald P. Radich, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MD, MBBS, Giovanni Martinelli, MD, Dong-Wook Kim, MD, PhD, Susan Branford, PhD, Martin C. Müller, MD, Yaping Shou, MD, PhD, Steven Novick, MD, PhD, Xiaolin Fan, PhD, Jorge E. Cortes, Michele Baccarani, MD, Hagop M. Kantarjian
Journal: Blood
Blood (2011) 118 (21): 3770.
https://doi.org/10.1182/blood.V118.21.3770.3770
Published: 2011